Final, 10-Year Outcomes with Nivolumab plus Ipilimumab in Advanced Melanoma.

Wolchok JD, Chiarion-Sileni V, Rutkowski P, Cowey CL, Schadendorf D, Wagstaff J, Queirolo P, Dummer R, Butler MO, Hill AG, Postow MA, Gaudy-Marqueste C, Medina T, Lao CD, Walker J, Márquez-Rodas I, Haanen JBAG, Guidoboni M, Maio M, Schöffski P, Carlino MS, Sandhu S, Lebbé C, Ascierto PA, Long GV, Ritchings C, Nassar A, Askelson M, Benito MP, Wang W, Hodi FS, Larkin J, CheckMate 067 Investigators

Open source

DOI: 10.1056/nejmoa2407417
Published: 2025 Jan 2
Container: The New England journal of medicine
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1056/nejmoa2407417,
  title = {Final, 10-Year Outcomes with Nivolumab plus Ipilimumab in Advanced Melanoma.},
  author = {Wolchok JD and Chiarion-Sileni V and Rutkowski P and Cowey CL and Schadendorf D and Wagstaff J and Queirolo P and Dummer R and Butler MO and Hill AG and Postow MA and Gaudy-Marqueste C and Medina T and Lao CD and Walker J and Márquez-Rodas I and Haanen JBAG and Guidoboni M and Maio M and Schöffski P and Carlino MS and Sandhu S and Lebbé C and Ascierto PA and Long GV and Ritchings C and Nassar A and Askelson M and Benito MP and Wang W and Hodi FS and Larkin J and CheckMate 067 Investigators},
  year = {2025},
  journal = {The New England journal of medicine},
  doi = {10.1056/nejmoa2407417},
  url = {https://doi.org/10.1056/nejmoa2407417}
}

RIS

TY  - JOUR
TI  - Final, 10-Year Outcomes with Nivolumab plus Ipilimumab in Advanced Melanoma.
AU  - Wolchok JD
AU  - Chiarion-Sileni V
AU  - Rutkowski P
AU  - Cowey CL
AU  - Schadendorf D
AU  - Wagstaff J
AU  - Queirolo P
AU  - Dummer R
AU  - Butler MO
AU  - Hill AG
AU  - Postow MA
AU  - Gaudy-Marqueste C
AU  - Medina T
AU  - Lao CD
AU  - Walker J
AU  - Márquez-Rodas I
AU  - Haanen JBAG
AU  - Guidoboni M
AU  - Maio M
AU  - Schöffski P
AU  - Carlino MS
AU  - Sandhu S
AU  - Lebbé C
AU  - Ascierto PA
AU  - Long GV
AU  - Ritchings C
AU  - Nassar A
AU  - Askelson M
AU  - Benito MP
AU  - Wang W
AU  - Hodi FS
AU  - Larkin J
AU  - CheckMate 067 Investigators
PY  - 2025
JO  - The New England journal of medicine
DO  - 10.1056/nejmoa2407417
UR  - https://doi.org/10.1056/nejmoa2407417
ER  -

APA

JD, W., V, C., P, R., CL, C., D, S., J, W., P, Q., R, D., MO, B., AG, H., MA, P., C, G., T, M., CD, L., J, W., I, M., JBAG, H., M, G., M, M., P, S., MS, C., S, S., C, L., PA, A., GV, L., C, R., A, N., M, A., MP, B., W, W., FS, H., J, L., & Investigators, C. 0. (2025). Final, 10-Year Outcomes with Nivolumab plus Ipilimumab in Advanced Melanoma.. The New England journal of medicine. https://doi.org/10.1056/nejmoa2407417

Source records

pubmed · retrieved 2026-09-25T10:16:11.019Z